Tolebrutinib has been approved in the European Union for the treatment of secondary progressive multiple sclerosis (SPMS) for…
Articles by Lindsey Shapiro, PhD
Scientists have identified six proteins that could serve as targets for new treatments designed to slow multiple sclerosis (MS)…
Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing…
An app-based, one-to-one peer support program from Shift.ms that connects people newly diagnosed with multiple sclerosis (MS) with…
Three years of treatment with Sanofi’s investigational antibody therapy frexalimab was associated with persistently low disease activity and…
Subjective, patient-reported data on lived experiences should always be considered in the care of chronic conditions like multiple sclerosis…
The understanding and management of neuropsychiatric symptoms such as depression and cognitive difficulties in multiple sclerosis (MS) have advanced…
The Consortium of Multiple Sclerosis Centers (CMSC) 2026 annual meeting kicks off today in Charlotte, North Carolina, bringing together…
Leaders in multiple sclerosis (MS) research and care are preparing to gather in Charlotte, North Carolina, for the…
Ocrevus (ocrelizumab) delayed disability progression and worsening hand function among a large group of people with primary progressive…
Real-world use of Octave Bioscience’s artificial intelligence (AI)-powered blood test for classifying multiple sclerosis (MS) activity has increased…
First-line treatment with Ocrevus (ocrelizumab) preserved walking abilities and hand function in most people with early relapsing-remitting multiple…
A clinical trial testing TG Therapeutics‘ CD20 inhibitor Briumvi (ublituximab-xiiy) in children with relapsing forms of multiple…
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis…
A Canadian study is challenging the growing belief that previous infection with the Epstein-Barr virus (EBV) is necessary for…
The investigational BTK inhibitor tolebrutinib did not lower the risk of confirmed disability progression compared with placebo in people…
The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk…
Researchers have developed a mouse model designed to reflect the disability worsening that occurs in the absence of relapses for…
Researchers and clinicians are gathering in San Diego and online for the 11th annual Americas Committee for Treatment and…
Some older people with multiple sclerosis (MS), namely those older than 60, may be able to safely discontinue…
A stem cell transplant may offer better long-term results for people with aggressive multiple sclerosis (MS) compared with standard…
A new model using artificial intelligence (AI) suggests that multiple sclerosis (MS) progression is better viewed along a single…
While certain autoimmune diseases are linked to an increased risk of digestive system cancers, people with multiple sclerosis (MS)…
More people with multiple sclerosis (MS) are using diet modifications to boost well-being and to manage symptoms, but there’s…
Experts are calling for tailored strategies to enhance the diagnosis, treatment, and monitoring of older people with multiple sclerosis…
A global clinical trial has been launched to evaluate the oral therapy candidate BMS-986368 for treating spasticity — muscle…
Researchers have developed a blood test to identify people at risk of developing multiple sclerosis (MS) years before the…
Artificial intelligence (AI)-powered algorithms to analyze data collected on a smartphone app could predict whether a person with multiple…
The use of B-cell depleting therapies does not increase the risk of an infection with COVID-19 among people with…
A particular finding on an MRI scan, called the central vein sign (CVS), is sufficient to support a multiple…